APO Research
Talk to an analyst

APO RESEARCH · REPORT

Third Party Clinical Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Third Party Clinical Testing Market Analysis and Forecast 2026-2032

2 May 2026189 pages

Choose your research edition.

Industry ResearchThird Party Clinical Testing Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Third Party Clinical Testing Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Third Party Clinical Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Third Party Clinical Testing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Third Party Clinical Testing Market Analysis and Forecast 2026-2032189 pages · $4,950 USD

Market perspective

The global Third Party Clinical Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Third Party Clinical Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Third Party Clinical Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Third Party Clinical Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Third Party Clinical Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Third Party Clinical Testing include Labcorp, IQVIA, PAREXEL International Corporation, ICON Plc, Charles River Laboratories, Syneos Health, PPD (Pharmaceutical Product Development), Medpace and WuXi AppTec, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Third Party Clinical Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Third Party Clinical Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Third Party Clinical Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Third Party Clinical Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Third Party Clinical Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Third Party Clinical Testing revenue, projected growth trends, production technology, application and end-user industry.

Third Party Clinical Testing Segment by Company

Labcorp

IQVIA

PAREXEL International Corporation

ICON Plc

Charles River Laboratories

Syneos Health

PPD (Pharmaceutical Product Development)

Medpace

WuXi AppTec

Kingmed

Dian Diagnostics

Adicon Clinical Laboratories

Kindstar

DaAn Gene

Berry Genomics

Frontage Holdings

Centre Testing International

Shanghai Labway Clinical Laboratory

Third Party Clinical Testing Segment by Type

Biochemical Tests

Immunity Tests

Routine Blood Tests

Others

Third Party Clinical Testing Segment by Application

Personal

Enterprise

Third Party Clinical Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Third Party Clinical Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Third Party Clinical Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Third Party Clinical Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Third Party Clinical Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Third Party Clinical Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Third Party Clinical Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Third Party Clinical Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biochemical Tests Major Player Table 3. Immunity Tests Major Player Table 4. Routine Blood Tests Major Player Table 5. Others Major Player Table 6. Global Third Party Clinical Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Personal Major Player Table 8. Enterprise Major Player Table 9. Third Party Clinical Testing Industry Trends Table 10. Third Party Clinical Testing Industry Drivers Table 11. Third Party Clinical Testing Industry Opportunities and Challenges Table 12. Third Party Clinical Testing Industry Restraints Table 13. Global Third Party Clinical Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Third Party Clinical Testing Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Third Party Clinical Testing Market Share by Region (2021-2026) Table 16. Global Third Party Clinical Testing Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Third Party Clinical Testing Market Share by Region (2027-2032) Table 18. Global Third Party Clinical Testing Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Third Party Clinical Testing Revenue Market Share by Players (2021-2026) Table 20. Global Third Party Clinical Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Third Party Clinical Testing Key Players Headquarters & Area Served Table 22. Global Third Party Clinical Testing Players, Product Type & Application Table 23. Global Third Party Clinical Testing Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Third Party Clinical Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Third Party Clinical Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Third Party Clinical Testing Revenue Market Share by Type (2021-2026) Table 30. Global Third Party Clinical Testing Revenue Market Share by Type (2027-2032) Table 31. Global Third Party Clinical Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Third Party Clinical Testing Revenue Market Share by Application (2021-2026) Table 35. Global Third Party Clinical Testing Revenue Market Share by Application (2027-2032) Table 36. Labcorp Company Information Table 37. Labcorp Business Overview Table 38. Labcorp Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Labcorp Third Party Clinical Testing Product Portfolio Table 40. Labcorp Recent Development Table 41. IQVIA Company Information Table 42. IQVIA Business Overview Table 43. IQVIA Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. IQVIA Third Party Clinical Testing Product Portfolio Table 45. IQVIA Recent Development Table 46. PAREXEL International Corporation Company Information Table 47. PAREXEL International Corporation Business Overview Table 48. PAREXEL International Corporation Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. PAREXEL International Corporation Third Party Clinical Testing Product Portfolio Table 50. PAREXEL International Corporation Recent Development Table 51. ICON Plc Company Information Table 52. ICON Plc Business Overview Table 53. ICON Plc Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. ICON Plc Third Party Clinical Testing Product Portfolio Table 55. ICON Plc Recent Development Table 56. Charles River Laboratories Company Information Table 57. Charles River Laboratories Business Overview Table 58. Charles River Laboratories Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Charles River Laboratories Third Party Clinical Testing Product Portfolio Table 60. Charles River Laboratories Recent Development Table 61. Syneos Health Company Information Table 62. Syneos Health Business Overview Table 63. Syneos Health Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Syneos Health Third Party Clinical Testing Product Portfolio Table 65. Syneos Health Recent Development Table 66. PPD (Pharmaceutical Product Development) Company Information Table 67. PPD (Pharmaceutical Product Development) Business Overview Table 68. PPD (Pharmaceutical Product Development) Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. PPD (Pharmaceutical Product Development) Third Party Clinical Testing Product Portfolio Table 70. PPD (Pharmaceutical Product Development) Recent Development Table 71. Medpace Company Information Table 72. Medpace Business Overview Table 73. Medpace Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Medpace Third Party Clinical Testing Product Portfolio Table 75. Medpace Recent Development Table 76. WuXi AppTec Company Information Table 77. WuXi AppTec Business Overview Table 78. WuXi AppTec Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. WuXi AppTec Third Party Clinical Testing Product Portfolio Table 80. WuXi AppTec Recent Development Table 81. Kingmed Company Information Table 82. Kingmed Business Overview Table 83. Kingmed Third Party Clinical Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Kingmed Third Party Clinical Testing Product Portfolio Table 85. Kingmed Recent Development Table 86. Dian Diagnostics Company Information Table 87. Dian Diagnostics Business Overview Table 88. Dian Diagnostics Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Dian Diagnostics Third Party Clinical Testing Product Portfolio Table 90. Dian Diagnostics Recent Development Table 91. Adicon Clinical Laboratories Company Information Table 92. Adicon Clinical Laboratories Business Overview Table 93. Adicon Clinical Laboratories Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Adicon Clinical Laboratories Third Party Clinical Testing Product Portfolio Table 95. Adicon Clinical Laboratories Recent Development Table 96. Kindstar Company Information Table 97. Kindstar Business Overview Table 98. Kindstar Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Kindstar Third Party Clinical Testing Product Portfolio Table 100. Kindstar Recent Development Table 101. DaAn Gene Company Information Table 102. DaAn Gene Business Overview Table 103. DaAn Gene Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. DaAn Gene Third Party Clinical Testing Product Portfolio Table 105. DaAn Gene Recent Development Table 106. Berry Genomics Company Information Table 107. Berry Genomics Business Overview Table 108. Berry Genomics Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Berry Genomics Third Party Clinical Testing Product Portfolio Table 110. Berry Genomics Recent Development Table 111. Frontage Holdings Company Information Table 112. Frontage Holdings Business Overview Table 113. Frontage Holdings Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Frontage Holdings Third Party Clinical Testing Product Portfolio Table 115. Frontage Holdings Recent Development Table 116. Centre Testing International Company Information Table 117. Centre Testing International Business Overview Table 118. Centre Testing International Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Centre Testing International Third Party Clinical Testing Product Portfolio Table 120. Centre Testing International Recent Development Table 121. Shanghai Labway Clinical Laboratory Company Information Table 122. Shanghai Labway Clinical Laboratory Business Overview Table 123. Shanghai Labway Clinical Laboratory Third Party Clinical Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Shanghai Labway Clinical Laboratory Third Party Clinical Testing Product Portfolio Table 125. Shanghai Labway Clinical Laboratory Recent Development Table 126. North America Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Third Party Clinical Testing Revenue by Country (2021-2026) & (US$ Million) Table 132. North America Third Party Clinical Testing Revenue by Country (US$ Million) & (2027-2032) Table 133. Europe Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 134. Europe Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 135. Europe Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Third Party Clinical Testing Revenue by Country (2021-2026) & (US$ Million) Table 139. Europe Third Party Clinical Testing Revenue by Country (US$ Million) & (2027-2032) Table 140. China Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 141. China Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 142. China Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 143. China Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 145. Asia Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 146. Asia Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 147. Asia Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 148. Asia Third Party Clinical Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Asia Third Party Clinical Testing Revenue by Region (US$ Million) & (2021-2026) Table 150. Asia Third Party Clinical Testing Revenue by Region (US$ Million) & (2027-2032) Table 151. SAMEA Third Party Clinical Testing Revenue by Type (2021-2026) & (US$ Million) Table 152. SAMEA Third Party Clinical Testing Revenue by Type (2027-2032) & (US$ Million) Table 153. SAMEA Third Party Clinical Testing Revenue by Application (2021-2026) & (US$ Million) Table 154. SAMEA Third Party Clinical Testing Revenue by Application (2027-2032) & (US$ Million) Table 155. SAMEA Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. SAMEA Third Party Clinical Testing Revenue by Country (2021-2026) & (US$ Million) Table 157. SAMEA Third Party Clinical Testing Revenue by Country (US$ Million) & (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Third Party Clinical Testing Image Figure 2. Global Third Party Clinical Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Third Party Clinical Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biochemical Tests Image Figure 5. Immunity Tests Image Figure 6. Routine Blood Tests Image Figure 7. Others Image Figure 8. Global Third Party Clinical Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Third Party Clinical Testing Market Size Share 2021 VS 2025 VS 2032 Figure 10. Personal Image Figure 11. Enterprise Image Figure 12. Global Third Party Clinical Testing Market Size (US$ Million) & (2021-2032) Figure 13. Global Third Party Clinical Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Third Party Clinical Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Third Party Clinical Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Third Party Clinical Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Third Party Clinical Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Third Party Clinical Testing Revenue Market Share by Type (2021-2032) Figure 20. Global Third Party Clinical Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Third Party Clinical Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Third Party Clinical Testing Revenue Market Share by Application (2021-2032) Figure 23. North America Third Party Clinical Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Third Party Clinical Testing Revenue Share by Type (2021-2032) Figure 25. North America Third Party Clinical Testing Revenue Share by Application (2021-2032) Figure 26. North America Third Party Clinical Testing Revenue Share by Country (2021-2032) Figure 27. United States Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Third Party Clinical Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Third Party Clinical Testing Revenue Share by Type (2021-2032) Figure 32. Europe Third Party Clinical Testing Revenue Share by Application (2021-2032) Figure 33. Europe Third Party Clinical Testing Revenue Share by Country (2021-2032) Figure 34. Germany Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Third Party Clinical Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Third Party Clinical Testing Revenue Share by Type (2021-2032) Figure 44. China Third Party Clinical Testing Revenue Share by Application (2021-2032) Figure 45. Asia Third Party Clinical Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Third Party Clinical Testing Revenue Share by Type (2021-2032) Figure 47. Asia Third Party Clinical Testing Revenue Share by Application (2021-2032) Figure 48. Asia Third Party Clinical Testing Revenue Share by Region (2021-2032) Figure 49. Japan Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Third Party Clinical Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Third Party Clinical Testing Revenue Share by Type (2021-2032) Figure 57. SAMEA Third Party Clinical Testing Revenue Share by Application (2021-2032) Figure 58. SAMEA Third Party Clinical Testing Revenue Share by Country (2021-2032) Figure 59. Brazil Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Third Party Clinical Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Biochemical Tests
  • Immunity Tests
  • Routine Blood Tests
  • Others
Applications
  • Personal
  • Enterprise
Companies covered
  • Labcorp
  • IQVIA
  • PAREXEL International Corporation
  • ICON Plc
  • Charles River Laboratories
  • Syneos Health
  • PPD (Pharmaceutical Product Development)
  • Medpace
  • WuXi AppTec
  • Kingmed
  • Dian Diagnostics
  • Adicon Clinical Laboratories
  • Kindstar
  • DaAn Gene
  • Berry Genomics
  • Frontage Holdings
  • Centre Testing International
  • Shanghai Labway Clinical Laboratory

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Third Party Clinical Testing Market by Type
  3. 1.2.1 Global Third Party Clinical Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biochemical Tests
  5. 1.2.3 Immunity Tests
  6. 1.2.4 Routine Blood Tests
  7. 1.2.5 Others
  8. 1.3 Third Party Clinical Testing Market by Application
  9. 1.3.1 Global Third Party Clinical Testing Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Personal
  11. 1.3.3 Enterprise
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Third Party Clinical Testing Market Dynamics
  1. 2.1 Third Party Clinical Testing Industry Trends
  2. 2.2 Third Party Clinical Testing Industry Drivers
  3. 2.3 Third Party Clinical Testing Industry Opportunities and Challenges
  4. 2.4 Third Party Clinical Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Third Party Clinical Testing Market Perspective (2021-2032)
  2. 3.2 Global Third Party Clinical Testing Growth Trends by Region
  3. 3.2.1 Global Third Party Clinical Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Third Party Clinical Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Third Party Clinical Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Third Party Clinical Testing Revenue by Players
  2. 4.1.1 Global Third Party Clinical Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Third Party Clinical Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Third Party Clinical Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Third Party Clinical Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Third Party Clinical Testing Key Players Headquarters & Area Served
  7. 4.4 Global Third Party Clinical Testing Players, Product Type & Application
  8. 4.5 Global Third Party Clinical Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Third Party Clinical Testing Market CR5 and HHI
  11. 4.6.3 2025 Third Party Clinical Testing Tier 1, Tier 2, and Tier 3
5 Third Party Clinical Testing Market Size by Type
  1. 5.1 Global Third Party Clinical Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 5.3 Global Third Party Clinical Testing Revenue Market Share by Type (2021-2032)
6 Third Party Clinical Testing Market Size by Application
  1. 6.1 Global Third Party Clinical Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Third Party Clinical Testing Revenue by Application (2021-2032)
  3. 6.3 Global Third Party Clinical Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Labcorp
  2. 7.1.1 Labcorp Company Information
  3. 7.1.2 Labcorp Business Overview
  4. 7.1.3 Labcorp Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Labcorp Third Party Clinical Testing Product Portfolio
  6. 7.1.5 Labcorp Recent Developments
  7. 7.2 IQVIA
  8. 7.2.1 IQVIA Company Information
  9. 7.2.2 IQVIA Business Overview
  10. 7.2.3 IQVIA Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 IQVIA Third Party Clinical Testing Product Portfolio
  12. 7.2.5 IQVIA Recent Developments
  13. 7.3 PAREXEL International Corporation
  14. 7.3.1 PAREXEL International Corporation Company Information
  15. 7.3.2 PAREXEL International Corporation Business Overview
  16. 7.3.3 PAREXEL International Corporation Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 PAREXEL International Corporation Third Party Clinical Testing Product Portfolio
  18. 7.3.5 PAREXEL International Corporation Recent Developments
  19. 7.4 ICON Plc
  20. 7.4.1 ICON Plc Company Information
  21. 7.4.2 ICON Plc Business Overview
  22. 7.4.3 ICON Plc Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 ICON Plc Third Party Clinical Testing Product Portfolio
  24. 7.4.5 ICON Plc Recent Developments
  25. 7.5 Charles River Laboratories
  26. 7.5.1 Charles River Laboratories Company Information
  27. 7.5.2 Charles River Laboratories Business Overview
  28. 7.5.3 Charles River Laboratories Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Charles River Laboratories Third Party Clinical Testing Product Portfolio
  30. 7.5.5 Charles River Laboratories Recent Developments
  31. 7.6 Syneos Health
  32. 7.6.1 Syneos Health Company Information
  33. 7.6.2 Syneos Health Business Overview
  34. 7.6.3 Syneos Health Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Syneos Health Third Party Clinical Testing Product Portfolio
  36. 7.6.5 Syneos Health Recent Developments
  37. 7.7 PPD (Pharmaceutical Product Development)
  38. 7.7.1 PPD (Pharmaceutical Product Development) Company Information
  39. 7.7.2 PPD (Pharmaceutical Product Development) Business Overview
  40. 7.7.3 PPD (Pharmaceutical Product Development) Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 PPD (Pharmaceutical Product Development) Third Party Clinical Testing Product Portfolio
  42. 7.7.5 PPD (Pharmaceutical Product Development) Recent Developments
  43. 7.8 Medpace
  44. 7.8.1 Medpace Company Information
  45. 7.8.2 Medpace Business Overview
  46. 7.8.3 Medpace Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Medpace Third Party Clinical Testing Product Portfolio
  48. 7.8.5 Medpace Recent Developments
  49. 7.9 WuXi AppTec
  50. 7.9.1 WuXi AppTec Company Information
  51. 7.9.2 WuXi AppTec Business Overview
  52. 7.9.3 WuXi AppTec Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 WuXi AppTec Third Party Clinical Testing Product Portfolio
  54. 7.9.5 WuXi AppTec Recent Developments
  55. 7.10 Kingmed
  56. 7.10.1 Kingmed Company Information
  57. 7.10.2 Kingmed Business Overview
  58. 7.10.3 Kingmed Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Kingmed Third Party Clinical Testing Product Portfolio
  60. 7.10.5 Kingmed Recent Developments
  61. 7.11 Dian Diagnostics
  62. 7.11.1 Dian Diagnostics Company Information
  63. 7.11.2 Dian Diagnostics Business Overview
  64. 7.11.3 Dian Diagnostics Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dian Diagnostics Third Party Clinical Testing Product Portfolio
  66. 7.11.5 Dian Diagnostics Recent Developments
  67. 7.12 Adicon Clinical Laboratories
  68. 7.12.1 Adicon Clinical Laboratories Company Information
  69. 7.12.2 Adicon Clinical Laboratories Business Overview
  70. 7.12.3 Adicon Clinical Laboratories Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Adicon Clinical Laboratories Third Party Clinical Testing Product Portfolio
  72. 7.12.5 Adicon Clinical Laboratories Recent Developments
  73. 7.13 Kindstar
  74. 7.13.1 Kindstar Company Information
  75. 7.13.2 Kindstar Business Overview
  76. 7.13.3 Kindstar Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Kindstar Third Party Clinical Testing Product Portfolio
  78. 7.13.5 Kindstar Recent Developments
  79. 7.14 DaAn Gene
  80. 7.14.1 DaAn Gene Company Information
  81. 7.14.2 DaAn Gene Business Overview
  82. 7.14.3 DaAn Gene Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  83. 7.14.4 DaAn Gene Third Party Clinical Testing Product Portfolio
  84. 7.14.5 DaAn Gene Recent Developments
  85. 7.15 Berry Genomics
  86. 7.15.1 Berry Genomics Company Information
  87. 7.15.2 Berry Genomics Business Overview
  88. 7.15.3 Berry Genomics Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Berry Genomics Third Party Clinical Testing Product Portfolio
  90. 7.15.5 Berry Genomics Recent Developments
  91. 7.16 Frontage Holdings
  92. 7.16.1 Frontage Holdings Company Information
  93. 7.16.2 Frontage Holdings Business Overview
  94. 7.16.3 Frontage Holdings Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Frontage Holdings Third Party Clinical Testing Product Portfolio
  96. 7.16.5 Frontage Holdings Recent Developments
  97. 7.17 Centre Testing International
  98. 7.17.1 Centre Testing International Company Information
  99. 7.17.2 Centre Testing International Business Overview
  100. 7.17.3 Centre Testing International Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Centre Testing International Third Party Clinical Testing Product Portfolio
  102. 7.17.5 Centre Testing International Recent Developments
  103. 7.18 Shanghai Labway Clinical Laboratory
  104. 7.18.1 Shanghai Labway Clinical Laboratory Company Information
  105. 7.18.2 Shanghai Labway Clinical Laboratory Business Overview
  106. 7.18.3 Shanghai Labway Clinical Laboratory Third Party Clinical Testing Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Shanghai Labway Clinical Laboratory Third Party Clinical Testing Product Portfolio
  108. 7.18.5 Shanghai Labway Clinical Laboratory Recent Developments
8 North America
  1. 8.1 North America Third Party Clinical Testing Revenue (2021-2032)
  2. 8.2 North America Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Third Party Clinical Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Third Party Clinical Testing Revenue by Type (2027-2032)
  5. 8.3 North America Third Party Clinical Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Third Party Clinical Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Third Party Clinical Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Third Party Clinical Testing Revenue by Application (2027-2032)
  9. 8.5 North America Third Party Clinical Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Third Party Clinical Testing Revenue by Country
  11. 8.6.1 North America Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Third Party Clinical Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Third Party Clinical Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Third Party Clinical Testing Revenue (2021-2032)
  2. 9.2 Europe Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Third Party Clinical Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Third Party Clinical Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Third Party Clinical Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Third Party Clinical Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Third Party Clinical Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Third Party Clinical Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Third Party Clinical Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Third Party Clinical Testing Revenue by Country
  11. 9.6.1 Europe Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Third Party Clinical Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Third Party Clinical Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Third Party Clinical Testing Revenue (2021-2032)
  2. 10.2 China Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Third Party Clinical Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Third Party Clinical Testing Revenue by Type (2027-2032)
  5. 10.3 China Third Party Clinical Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Third Party Clinical Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Third Party Clinical Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Third Party Clinical Testing Revenue by Application (2027-2032)
  9. 10.5 China Third Party Clinical Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Third Party Clinical Testing Revenue (2021-2032)
  2. 11.2 Asia Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Third Party Clinical Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Third Party Clinical Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Third Party Clinical Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Third Party Clinical Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Third Party Clinical Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Third Party Clinical Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Third Party Clinical Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Third Party Clinical Testing Revenue by Country
  11. 11.6.1 Asia Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Third Party Clinical Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Third Party Clinical Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Third Party Clinical Testing Revenue (2021-2032)
  2. 12.2 SAMEA Third Party Clinical Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Third Party Clinical Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Third Party Clinical Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Third Party Clinical Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Third Party Clinical Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Third Party Clinical Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Third Party Clinical Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Third Party Clinical Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Third Party Clinical Testing Revenue by Country
  11. 12.6.1 SAMEA Third Party Clinical Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Third Party Clinical Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Third Party Clinical Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst